Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 13,817,000 |
|
|||||
| News | - | ||||||
| Day High | 0.0012 | Low High |
|||||
| Day Low | 0.0008 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Endonovo Therapeutics Inc (PK) | ENDV | OTCMarkets | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.0001 | -11.11% | 0.0008 | 16:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.001 | 0.0008 | 0.0012 | 0.0008 | 0.0009 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 64 | 13,817,000 | US$ 0.001048 | US$ 14,484 | - | 0.0007 - 0.01739 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 14:40:58 | 1,000,000 | US$ 0.0008 | USD |
Endonovo Therapeutics Inc (PK) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 0 | 277.95M | 117.21M | 140k | 6.93M | 0.02 | 0.00 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Endonovo Therapeutics (PK) News
| Date | Time | Source | News Article |
|---|---|---|---|
| 2/02/2024 | 16:23 | Edgar (US Regulatory) | Form 15-12G - Securities registration termination [Section.. |
| 1/03/2024 | 16:30 | Edgar (US Regulatory) | Form 8-K - Current report |
| 12/29/2023 | 14:20 | Edgar (US Regulatory) | Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]:.. |
| 12/04/2023 | 08:08 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/15/2023 | 11:21 | Edgar (US Regulatory) | Form NT 10-Q - Notification of inability to timely file Form.. |
| 10/12/2023 | 05:03 | Edgar (US Regulatory) | Form 8-K - Current report |
| 8/25/2023 | 06:04 | Edgar (US Regulatory) | Form 1-A/A - Offering Statement [Regulation A]: [Amend] |
| 8/21/2023 | 16:16 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ENDV Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.0011 | 0.0012 | 0.0007 | 0.0008993 | 2,933,242 | -0.0003 | -27.27% |
| 1 Month | 0.0014 | 0.0018 | 0.0007 | 0.0010421 | 3,689,178 | -0.0006 | -42.86% |
| 3 Months | 0.0022 | 0.0058 | 0.0007 | 0.001923 | 2,662,042 | -0.0014 | -63.64% |
| 6 Months | 0.00905 | 0.0134 | 0.0007 | 0.0023181 | 1,425,842 | -0.00825 | -91.16% |
| 1 Year | 0.0138 | 0.01739 | 0.0007 | 0.0031498 | 810,878 | -0.013 | -94.20% |
| 3 Years | 0.030315 | 0.06 | 0.0007 | 0.0088375 | 457,510 | -0.02952 | -97.36% |
| 5 Years | 0.0147 | 3.90 | 0.0007 | 0.0172195 | 1,053,793 | -0.0139 | -94.56% |
Endonovo Therapeutics (PK) Description
| Endonovo Therapeutics (OTCQB: ENDV) is a commercial stage developer of non-invasive medical devices designed to deliver its proprietary Electroceutical Therapy for the treatment of inflammatory conditions, cardiovascular diseases and central nervous system disorders. Endonovo's Electroceutical Therapy is FDA-Cleared for the palliative treatment of pain and post-surgical edema (swelling) and CE Marked for the promotion of wound healing and the palliative treatment of pain and post-surgical edema. Endonovo's Electroceutical Therapy has CMS National Coverage for the treatment of chronic wounds. The Company's current pipeline of clinical-stage Electroceutical Therapies targets cardiovascular diseases and central nervous system disorders, including ischemic heart disease, acute concussions, post-concussion syndrome, traumatic brain injury (TBI) and multiple sclerosis. |
